Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial - Concepedia

Concepedia

Publication | Open Access

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial

DOI Full Paper Access

55

Citations

22

References

2017

Year

Richard Adams, Ewan Brown, Louise Brown, Rachel Butler, Stephen Falk, David J. Fisher, Richard Kaplan, Philip Quirke, Susan D. Richman, Leslie Samuel,

The Lancet. Gastroenterology & hepatology

Abstract

Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme, Cancer Research UK, NIHR Clinical Trials Research Network, Health and Care Research Wales, and AstraZeneca.

References

	Year	Citations

Page 1